Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc > I strongly believe that this stock has potential

<< Previous

Bullboard Posts

Next >>

Comment by Peanutbudderon Jan 10, 2018 4:15pm

45 Views

Post# 27327507

RE:RE:RE:I strongly believe that this stock has potential

peer reviewed study in 2012 estimated that one per cent of U.S. electricity use came from indoor marijuana operations. In California, the top-producing state, indoor cultivation was responsible for about three per cent of electricity use, or equivalent to that of one million homes, wrote Evan Mills, a senior scientist in energy technologies at the Lawrence Berkeley National Laboratory.

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload